 Countries included in the analysis were: France, Germany, Italy, Spain and the United Kingdom (UK).  Oncology drugs for which a marketing authorization was granted by the EC centralized procedure between January 2015 and December 2016 were extracted for the analysis from the European Medicines Agency (EMA) website 2 .
-Only initial authorizations were considered.  Commercialization status was confirmed via country-specific health authorities' official websites (Table 1 ). -Oncology drugs that followed an early access pathway (commercialized before receiving the marketing authorization) in France and those that were approved with C-nn class (commercialized even if not yet reimbursed) in Italy were also considered as commercialized.  The official ex-factory list prices were extracted through country-specific official sources (Table 1 ).
-National statutory discounts to drug prices were considered in Spain (Royal DecreeLaw 8/2010 3 ) and Italy (Determinations of July 2006 and September 2006) . -In Germany, prices after the early benefit assessment were included.  Market access was analyzed considering the percentage of drugs commercialized at a national level with respect to all oncology drugs approved at EU level.  In order to have an anchor price for the comparison, the country with the lowest expected price, i.e. UK, was chosen to be compared with.  Figure 1 shows the percentage of oncology drugs commercialized at the national level.
-Germany was the country with the highest number of oncology drugs commercialized, while the least access was in Spain.
-11 approved oncology drugs have been commercialized in all EU5 countries.
-6 out of 18 (32%) commercialized drugs were approved with C-nn class in Italy and 10 out of 19 (53%) drugs were introduced through early access to medicines scheme in France.  26 oncology drugs were authorized by the EC between January 2015 and December 2016 (Table 2) .  Compared with the UK, the prices of oncology drugs are higher in Spain, Italy and France. However, the prices after the early benefit assessment are lower in Germany (Figure 2 ).
Figure 2. Price differences across the EU5 (median [IQR]) DISCUSSION
 Hidden discounts, performance agreement and budget cap that are increasingly common in Europe are unrevealed 13 .
-The frequency and complexity of confidential negotiations suggests that the official list prices may not represent the reimbursed price paid by many institutional payers 13 .
 The joint analysis of EU5 countries is important in order to understand differences in market access and pricing processes across countries and to implement strategies accordingly.
-The transparency of negotiated prices would allow to perform better and more realistic price comparisons across these countries.
 National/regional budgets and negotiations in other countries play an important role in achieving price agreements at a national level, which delays the availability of new drugs to patients.
 A potential reason for unknown list prices of commercialized medicines might be that some drugs were introduced with an early access to medicines scheme, in which price and reimbursement are still not negotiated.
CONCLUSIONS
 Wide disparity exists in the number of approved drugs available in each of the European countries since the proportion of oncology drugs commercialized varies from 54% to 92%.
 More than half of the oncology drugs are still not commercialized in all the countries.
 The price analysis performed shows that substantial differences exist across countries. 
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